insights_auto
Kodėl „LILY34“ padidėjo 3,01%?
Įsigilintichevron_right
LILY34:BVMF
Eli Lilly and Company
280,35 BRL
arrow_upward
+3,01%(+8,20) 1 D.
11-16, 11:49:54 GMT−3 · BRL
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „LILY34“ įžvalgos...
Atidaryti
276,57 BRL
Aukšta
281,60 BRL
Žema
274,86 BRL
Rinkos kapitalizacija
1,38 trln.
Vid. kiekis
52,12 tūkst.
Apimtis
13,85 tūkst.
52 sav. aukšta
281,60 BRL
52 sav. žema
141,59 BRL
Neapmokėtos akcijos
940,75 mln.
Darbuotojų skaičius
50 tūkst.
Atidaryti
276,57 BRL
Aukšta
281,60 BRL
Žema
274,86 BRL
Rinkos kapitalizacija
1,38 trln.
Vid. kiekis
52,12 tūkst.
Apimtis
13,85 tūkst.
52 sav. aukšta
281,60 BRL
52 sav. žema
141,59 BRL
Neapmokėtos akcijos
940,75 mln.
Darbuotojų skaičius
50 tūkst.
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
Yahoo Finance
·
prieš 1 valandą
Eli Lilly to Acquire Calytrix Bio for Up to $1.5 Billion to Expand Blood Cancer Portfolio
Yahoo Finance
·
prieš 2 valandas
Lilly adds to buyout streak with $1.5B purchase of startup Calytrix
Reuters
·
prieš 2 valandas
Lilly to buy Calytrix Bio for up to $1.5 billion
marketscreener.com
·
prieš 3 valandas
Barclays Adjusts Price Target on Eli Lilly and Company to $1,550 From $1,400
Profilis
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 36 countries. Its products are marketed in approximately 90 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so.
The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes. Wikipedia
Apie „Eli Lilly and Company“
Generalinis direktoriusDavid A. Ricks
Darbuotojai50 tūkst.
Įkurta1876
Pagrindinė būstinėIndianapolis, Indiana, Jungtinės Valstijos
SektoriusHealth Care
Pramonės sritis-
Svetainėlilly.com